FDA Letters Issued in January 2026

FDA's complete response letter contains source-text evidence related to Clinical efficacy and substantial evidence, Device constituent and human factors, Safety and adverse events, Bioequivalence and pharmacokinetics. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.

FDA issued an approval letter for RIZAFILM on 2026-01-30. The source metadata identifies NDA 205394 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for LORBRENA on 2026-01-30. The source metadata identifies NDA 210868 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for WEGOVY, WEGOVY HD, WEGOVY FLEXTOUCH on 2026-01-30. The source metadata identifies NDA 215256, NDA 218316 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for XIMINO on 2026-01-30. The source metadata identifies NDA 201922 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to gotpouches.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Cohance Lifesciences Limited concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to niqpouches.com concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for ABILIFY MAINTENA KIT on 2026-01-29. The source metadata identifies NDA 202971 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for VFEND on 2026-01-29. The source metadata identifies NDA 021266, NDA 021267, NDA 021630 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for YUVEZZI on 2026-01-29. The source metadata identifies NDA 220142 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Central Coast Multispecialty Medical Group, Inc. concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Fidelity Melon, Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Diasol, Inc. concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Laboratory controls and testing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA's complete response letter contains source-text evidence related to Labeling, packaging, and proprietary name, Clinical efficacy and substantial evidence, Safety and adverse events, Statistical analysis. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.

FDA issued an approval letter for IDOSE TR on 2026-01-28. The source metadata identifies NDA 218010 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for VYXEOS on 2026-01-28. The source metadata identifies NDA 209401 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for CAPRELSA on 2026-01-28. The source metadata identifies NDA 022405 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for PRIFTIN on 2026-01-28. The source metadata identifies NDA 021024 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for DARZALEX FASPRO on 2026-01-28. The source metadata identifies BLA 761145 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for IDOSE TR on 2026-01-28. The source metadata identifies NDA 218010 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Beta Bionics, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Beta Bionics, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Medical device quality and reporting, Labeling, claims, and misbranding, Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for NOXAFIL, NOXAFIL POWDERMIX KIT on 2026-01-27. The source metadata identifies NDA 022003, NDA 205053, NDA 205596, NDA 214770 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for QUIOFIC on 2026-01-27. The source metadata identifies NDA 216395 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for PONSTEL on 2026-01-27. The source metadata identifies NDA 015034 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Flextronics America LLC concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic full-text screening identifies discussion of Quality systems and CAPA, Manufacturing and CGMP controls, Medical device quality and reporting, Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Conceive Fertility Center concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). Deterministic full-text screening identifies discussion of Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to HTO Nevada, Inc. dba Kirkman concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for AFREZZA on 2026-01-26. The source metadata identifies BLA 022472 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for EPYSQLI on 2026-01-26. The source metadata identifies BLA 761340 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for JOURNAVX on 2026-01-26. The source metadata identifies NDA 219209 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for CALDOLOR on 2026-01-26. The source metadata identifies NDA 022348 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for SPRAVATO on 2026-01-26. The source metadata identifies NDA 211243 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for TEPYLUTE on 2026-01-23. The source metadata identifies NDA 216984 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ZILBRYSQ on 2026-01-23. The source metadata identifies NDA 216834 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Abbott Diabetes Care, Inc. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Intelligent Remedies, Inc. concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Louisville Reproductive Center concerning Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products (HCT/Ps). No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for BRIUMVI on 2026-01-22. The source metadata identifies BLA 761238 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER on 2026-01-22. The source metadata identifies NDA 019708 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for VERQUVO on 2026-01-22. The source metadata identifies NDA 214377 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for RYKINDO on 2026-01-22. The source metadata identifies NDA 212849 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for EVRYSDI on 2026-01-22. The source metadata identifies NDA 219285, NDA 213535 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for TYENNE on 2026-01-22. The source metadata identifies BLA 761275 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for AVTOZMA on 2026-01-22. The source metadata identifies BLA 761498 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ZYNLONTA on 2026-01-22. The source metadata identifies BLA 761196 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for IMPLANON, NEXPLANON on 2026-01-22. The source metadata identifies NDA 021529 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for LEQEMBI on 2026-01-22. The source metadata identifies BLA 761269 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Tombak LLC concerning Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding, Tobacco product authorization and marketing. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to South Bay Cold Storage & Handling, Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Diamond-Herpanacine of PA, Inc. concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for ZIRGAN on 2026-01-21. The source metadata identifies NDA 022211 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for LOTEPREDNOL ETABONATE AND TOBRAMYCIN on 2026-01-21. The source metadata identifies ANDA 217597 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ZEPBOUND (AUTOINJECTOR), ZEPBOUND, ZEPBOUND KWIKPEN on 2026-01-21. The source metadata identifies NDA 217806 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for MOUNJARO (AUTOINJECTOR), MOUNJARO, MOUNJARO KWIKPEN on 2026-01-21. The source metadata identifies NDA 215866 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Supersmart USA, LLC concerning New Drug/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Signature Formulations, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic full-text screening identifies discussion of Manufacturing and CGMP controls, Quality systems and CAPA, Laboratory controls and testing, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Naumes, Inc. concerning Food/Prepared Packed or Held Under Insanitary Conditions/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for ALVAIZ on 2026-01-20. The source metadata identifies NDA 216774 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for OTULFI on 2026-01-20. The source metadata identifies BLA 761379 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for FILKRI on 2026-01-20. The source metadata identifies BLA 761027 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for NAPROXEN SODIUM on 2026-01-20. The source metadata identifies NDA 021920 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to GenoGenix LLC concerning Compounding Pharmacy/Adulterated Drug Products. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding, Manufacturing and CGMP controls, Laboratory controls and testing, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for NEXLETOL on 2026-01-16. The source metadata identifies NDA 211616 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for NEXLIZET on 2026-01-16. The source metadata identifies NDA 211617 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for NARCAN on 2026-01-16. The source metadata identifies NDA 208411 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to East CK Trading Inc. concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Zip Foods Importers, Inc concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Feng Foods Trading Inc. concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Boothwyn Pharmacy, LLC concerning Compounding Pharmacy/Adulterated Drug Products. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for AVTOZMA on 2026-01-15. The source metadata identifies BLA 761420 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for GLEEVEC on 2026-01-15. The source metadata identifies NDA 021588 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ROGAINE (FOR MEN), ROGAINE (FOR WOMEN), ROGAINE EXTRA STRENGTH (FOR MEN) on 2026-01-15. The source metadata identifies NDA 019501, NDA 020834, NDA 021812 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for YESAFILI on 2026-01-15. The source metadata identifies BLA 761274 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to The Great Smart African Food LLC concerning Foreign Supplier Verification Program (FSVP). Deterministic source-metadata screening identifies discussion of Food safety and supplier verification. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Fulijaya Manufacturing SDN. BHD. concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Min Jiang Food Store Inc dba Koi Koi Trading concerning Seafood HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Deterministic full-text screening identifies discussion of Food safety and supplier verification, Manufacturing and CGMP controls, Quality systems and CAPA. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for CEREZYME on 2026-01-13. The source metadata identifies BLA 020367 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for DIROXIMEL FUMARATE on 2026-01-13. The source metadata identifies ANDA 218596 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for IOHEXOL on 2026-01-13. The source metadata identifies ANDA 217737 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE on 2026-01-13. The source metadata identifies ANDA 218273 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for PSEUDOEPHEDRINE HYDROCHLORIDE on 2026-01-13. The source metadata identifies ANDA 218854 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for SITAGLIPTIN AND METFORMIN HYDROCHLORIDE on 2026-01-13. The source metadata identifies ANDA 202388 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for CLADRIBINE on 2026-01-13. The source metadata identifies ANDA 218425 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for DIAZEPAM on 2026-01-13. The source metadata identifies ANDA 217468 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for SITAGLIPTIN PHOSPHATE on 2026-01-13. The source metadata identifies ANDA 202327 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for LINAGLIPTIN on 2026-01-13. The source metadata identifies ANDA 208431 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ESTRADIOL on 2026-01-13. The source metadata identifies ANDA 214137 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for BECLOMETHASONE DIPROPIONATE on 2026-01-13. The source metadata identifies ANDA 213811 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for RIMEGEPANT on 2026-01-13. The source metadata identifies ANDA 219399 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for ZYCUBO on 2026-01-13. The source metadata identifies NDA 211241 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Center For Immunology Science, LLC concerning Sponsor/Investigator. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA's complete response letter contains source-text evidence related to Clinical efficacy and substantial evidence, Safety and adverse events, Chemistry, manufacturing, and controls, Statistical analysis. Theme counts identify where the letter discusses a topic; they do not replace review of the exact redacted letter.

FDA issued an approval letter for ENSACOVE on 2026-01-09. The source metadata identifies NDA 218171 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to CC Pollen Company concerning CGMP/Dietary Supplement/Adulterated/Misbranded. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Germaphobix concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Christopher Dale Butler concerning Acidified Foods/Emergency Permit Control/Adulterated. No controlled compliance theme met the deterministic text-matching threshold; review the exact FDA web letter and any later response or closeout.

FDA issued an approval letter for ZEPBOUND (AUTOINJECTOR), ZEPBOUND, ZEPBOUND KWIKPEN on 2026-01-08. The source metadata identifies NDA 217806 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for AMONDYS 45 on 2026-01-08. The source metadata identifies NDA 213026 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for YESINTEK on 2026-01-08. The source metadata identifies BLA 761406 as an original application. Review the exact FDA letter for the approved conditions and labeling.

FDA issued an approval letter for MOUNJARO (AUTOINJECTOR), MOUNJARO, MOUNJARO KWIKPEN on 2026-01-08. The source metadata identifies NDA 215866 as a supplement. Review the exact FDA letter for the approved conditions and labeling.

FDA issued a warning letter to Prodrome Sciences USA, LLC concerning Sponsor/Unapproved Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Genovate concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic source-metadata screening identifies discussion of Unapproved products and premarket authorization. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Unomedical Device S.A. de C.V. concerning CGMP/QSR/Medical Devices/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Elanco Animal Health USA concerning False & Misleading Claims/Misbranded. Deterministic full-text screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Genetrace concerning Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA). Deterministic full-text screening identifies discussion of Unapproved products and premarket authorization, Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

FDA issued a warning letter to Winder Laboratories, LLC concerning CGMP/Finished Pharmaceuticals/Adulterated. Deterministic source-metadata screening identifies discussion of Manufacturing and CGMP controls. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.